Monitor for future clinical milestones, partnership developments, or additional IP filings; current announcement is speculative and preclinical, but could attract investor interest given the large target market.
Price Chart
Executive Summary
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs, has advanced its collaboration with Clearmind Medicine by publishing a PCT patent application for a novel MEAI-PEA combination therapy targeting obesity and MASLD. The press release highlights the potential of this non-hallucinogenic treatment as a safer, more cost-effective alternative to GLP-1 agonists, amid a rapidly growing global weight loss drug market.
Key Facts
- SciSparc holds ~75% ownership in NeuroThera Labs, which co-developed a patent-published combination therapy (MEAI-PEA) for obesity and MASLD.
- The therapy is positioned as a potential non-hallucinogenic, safer, and more cost-effective alternative to GLP-1 agonists.
- Global weight loss drug market was valued at $37B in 2025, projected to reach $226B by 2035.
- No clinical trial results, revenue, or funding details were disclosed — only patent publication and forward-looking statements.
Financial Impact
Potential long-term value if therapy advances clinically and commercially; no near-term financial impact due to early stage.
Risk Factors
- Therapy is in pre-patent publication stage with no clinical data yet — high development risk.
- Forward-looking statements dominate; actual outcomes may differ materially due to regulatory, clinical, or commercialization risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.29 | awaiting T+5 | — | $0.8500 (+34.08%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $0.8500 (−22.02%) |
Oct 22, 2026 5d ago | Press Release | $1.20 | awaiting T+5 | — | $0.8500 (−29.17%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $0.8500 (+57.50%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.8500 (−57.50%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.8500 (−57.50%) |
Oct 7, 2026 20d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $0.8500 (−81.68%) |
Sep 30, 2026 27d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $0.8500 (+81.32%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $0.8500 (−84.23%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $0.8500 (−83.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers